UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Boryung’s antihypertensive drug Kanarb tops output among new drugs
  • By So Jae-hyeon
  • Published 2018.05.08 16:05
  • Updated 2018.05.08 16:33
  • comments 0

Boryung Pharmaceutical’s antihypertensive treatment Kanarb ranked No. 1 in production among 29 new drugs developed in Korea, government data showed Tuesday.

According to the Ministry of Food and Drug Safety, novel drugs developed by domestic pharmaceutical firms posted 187.7 billion won ($174.1 million) in combined production last year, up 11.9 percent from 167. 7 billion won in 2016.

Kanarb’s output reached 40.2 billion won, the most among those 29 drugs.

Despite a 20.7 percent decline from the previous year’s 50.7 billion won production, Kanarb was the most produced local new drug in 2017.

Following Kanarb was LG Chem’s Zemiglo, an antidiabetic treatment that inhibits DPP-4 (dipeptidyl peptidase-4), which posted 32.7 billion won output last year. Zemiglo’s production last year rose 3.9 percent from 31.5 billion won in 2016.

Il-yang Pharmaceutical’s antiulcer drug Noltec grew 40.5 percent in annual output to reach 26.1 billion won in 2017, up from 18.6 billion won in the previous year.

Chong Kun Dang’s antidiabetic drug Duvie also saw its production increase by 1.3 percent to 16.4 billion won last year, compared to 16.1 billion won in 2016.

Daewoong Pharmaceutical’s osteoarthritis drug Pelubi recorded a 139.9 percent output growth from 4.4 billion won to 10.5 billion won during the same period.

Il-yang Pharm’s Supect, which recently lost its second-line indication for treatment of chronic myelogenous leukemia, registered 9.7 billion won output. JW Pharmaceutical’s Quinolone antibiotics Q-roxin posted 9 billion won.

Crystal Genomics’ nonsteroidal anti-inflammatory analgesic Acelex posted 7.8 billion won output, an increase of 124.2 percent compared to the previous year's 3.5 billion won. Kolon Life Science’s Invossa-K had 6.2 billion won production.

“Local new drugs’ outputs have been boosted by exports rather than domestic demands. In the long-term, drugmakers should enhance domestic sales as well,” a pharmaceutical source said.

sjh@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by So Jae-hyeon
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top